VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2021 | Second-generation BTK inhibitors and their clinical impact

Deborah M. Stephens, DO, of The University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, discusses second-generation ‎Bruton’s tyrosine kinase inhibitors (BTKis) and outlines the impact that they have had in clinical settings. Dr Stephens compares the toxicity and safety profile of ibrutinib, a first-generation BTKi, with second-generation BTKis such as acalabrutinib and zanubrutinib, suggesting that second-generation BTKis may become a more favourable treatment option. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter